Smith+Nephew announced it has been named the Preferred Sports Medicine Technology Partner of UFC. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies. Smith+Nephew offers world-class Sports Medicine solutions including advanced technologies, instruments and implants that enable surgeons to perform minimally invasive surgery including the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip and small joints.

Recent advancements in its biological healing portfolio include the REGENETEN Bioinductive Implant and the newly acquired CARTIHEAL AGILI-C Cartilage Repair Implant. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care. Beyond the Octagon, UFC and Smith+Nephew will collaborate on original content that will be distributed through UFC's popular digital and social channels, which reach more than 259 million users worldwide.

Smith+Nephew will also have a branded presence throughout the UFC Performance Institutes in Las Vegas, Shanghai and Mexico City - the world's first mixed martial arts performance training, research, rehabilitation, and nutrition centers. For example, statements regarding expected revenue growth and trading profit margins, market trends and product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", well-placed", "believe",estimate", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to supply chain or operations or those of suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, success in performing due diligence, evaluating and integrating acquired businesses.